Precision Medicine and Machine Learning to predict critical disease and death due to Coronavirus disease 2019 (COVID-19).

Authors

Júnior WLDT,Danelli T,Tano ZN,Cassela PLCS,Trigo GL,Cardoso KM,Loni LP,Ahrens TM,Espinosa BR,Fernandes AJ,Almeida ERD,Lozovoy MAB,Reiche EMV,Maes M,Simão ANC

Affiliations (15)

  • Infectious Diseases Unit, Department of Clinical Medicine, Health Sciences Center, State University of Londrina, Londrina, Paraná, Brazil. Electronic address: [email protected].
  • Infectious Diseases Unit, Department of Clinical Medicine, Health Sciences Center, State University of Londrina, Londrina, Paraná, Brazil. Electronic address: [email protected].
  • Infectious Diseases Unit, Department of Clinical Medicine, Health Sciences Center, State University of Londrina, Londrina, Paraná, Brazil. Electronic address: [email protected].
  • Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Paraná, Brazil. Electronic address: [email protected].
  • Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Paraná, Brazil. Electronic address: [email protected].
  • Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Paraná, Brazil. Electronic address: [email protected].
  • Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Paraná, Brazil. Electronic address: [email protected].
  • Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Paraná, Brazil. Electronic address: [email protected].
  • Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Paraná, Brazil. Electronic address: [email protected].
  • Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Paraná, Brazil. Electronic address: [email protected].
  • Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Paraná, Brazil; Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, University of Londrina, Londrina, Paraná, Brazil. Electronic address: [email protected].
  • Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Paraná, Brazil; Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, University of Londrina, Londrina, Paraná, Brazil. Electronic address: [email protected].
  • Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Paraná, Brazil; Pontifical Catholic University of Paraná, School of Medicine, Campus Londrina, Londrina, Paraná, Brazil. Electronic address: [email protected].
  • Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China; Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences, Chengdu 610072, China. Electronic address: [email protected].
  • Laboratory of Research in Applied Immunology, University Hospital of Londrina, University of Londrina, Londrina, Paraná, Brazil; Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, University of Londrina, Londrina, Paraná, Brazil. Electronic address: [email protected].

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Coronavirus Disease 2019 (COVID-19) and induces activation of inflammatory pathways, including the inflammasome. The aim was to construct Machine Learning (ML) models to predict critical disease and death in patients with COVID-19. A total of 528 individuals with SARS-CoV-2 infection were included, comprising 308 with critical and 220 with non-critical COVID-19. The ML models included imaging, demographic, inflammatory biomarkers, NLRP3 (rs10754558 and rs10157379) and IL18 (rs360717 and rs187238) inflammasome variants. Individuals with critical COVID-19 were older, higher male/female ratio, body mass index (BMI), rate of type 2 diabetes mellitus (T2DM), hypertension, inflammatory biomarkers, need of orotracheal intubation, intensive care unit admission, incidence of death, and sickness symptom complex (SSC) scores and lower peripheral oxygen saturation (SpO<sub>2</sub>) compared to those with non-critical disease. We found that 49.5 % of the variance in the severity of critical COVID-19 was explained by SpO<sub>2</sub> and SSC (negatively associated), chest computed tomography alterations (CCTA), inflammatory biomarkers, severe acute respiratory syndrome (SARS), BMI, T2DM, and age (positively associated). In this model, the NLRP3/IL18 variants showed indirect effects on critical COVID-19 that were mediated by inflammatory biomarkers, SARS, and SSC. Neural network models yielded a prediction of critical disease and death due to COVID-19 with an area under the receiving operating characteristic curve of 0.930 and 0.927, respectively. These ML methods increase the accuracy of predicting severity, critical illness, and mortality caused by COVID-19 and show that the genetic variants contribute to the predictive power of the ML models.

Topics

Journal Article

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.